Sai Life Sciences IPO analysis

Sai Life Sciences IPO (initial public offering) will open for subscription on December 11, 2024, and close on December 13, 2024. Below is a breakdown of the pharmaceutical contract research and manufacturing company's strengths, weaknesses and growth prospects to help investors make an informed decision.

Sai Life Sciences IPO in a nutshell

• Quality: Between FY22 and FY24, Sai Life Sciences reported an average three-year ROE and ROCE of around 4 and 5 per cent, respectively.
  
• Growth: During FY22-24, its revenue and net profit grew annually by nearly 30 and 265 per cent, respectively.
  
• Valuation: At the upper price band of Rs 549, the stock is valued at a P/E and P/B ratio of 92 and 6 times, respectively.
  
• Overview: Sai Life Sciences is a contract research, development and manufacturing organisation (CRDMO) that is set to benefit from increased pharmaceutical outsourcing, especially for R&D. Complex development processes, high costs, supply chain disruptions and regulatory compliance is expected to drive penetration of global R&D outsourcing services, benefitting Sai Life. However, the intense competition in the industry is a challenge.

About Sai Life Sciences

The company provides end-to-end services for small molecule new chemical entities (newly discovered chemical compounds) to global pharma and biotechnology companies. It derives nearly 43 per cent of its revenue from new drug discovery research and the rest from contract development and manufacturing. The company is export driven and derives 97 per cent of its business from the US, UK, Europe and Japan.

Strengths of Sai Life Sciences

• Integrated services: It provides services across the drug discovery, development and manufacturing value chain. This allows the company to provide end-to-end support and also acquire customers in the intermediate stages.
  
• Strong customer base: Its customer base includes global pharmaceutical giants, including 18 of the world's top 25 players by revenue (as of 2023). These include Pfizer, Johnson & Johnson, among others.

Weaknesses of Sai Life Sciences

• Client concentration: As of FY24, of the total 329 customers, the top 10 clients together contributed 46 per cent to company's revenue. This exposes it to adverse risk in case of any outsourcing demand disruption from any key clients.
  
• High employee expenses: The company's three-year average employee benefit expenses were a staggering 34 per cent of its revenue. As a result, the company has the lowest EBIT margin at 11.3 per cent among peers, despite having high gross margins.

Risk report

Company and business

• Did Sai Life Sciences report earnings before tax of Rs 50 crore or more in the last 12 months?
  Yes. The company reported an earnings before tax of Rs 166 crore for 12 months ending September 2024.
  
• Will the company be able to scale up its business?
  Yes. The global small molecule CRDMO industry is projected to comprise nearly 53 per cent of the overall CRDMO market by 2028, driven by increasing pharmaceutical and biotech research and development outsourcing. This should help the company scale up.
  
• Does the company have recognisable brands with client stickiness?
  Yes. During FY24, it served more than 280 pharmaceutical companies, including 18 of the top 25 players globally. Further, it has maintained relationships with its top 10 customers for an average of 12 years.
  
• Does the company have a credible moat?
  No. There are many big players present in the industry. The pricing power also rests with the customers.

Management

• Do any of the company's founders still hold at least a 5 per cent stake? Or do promoters hold more than a 25 per cent stake in the company?
  Yes. After the IPO, the promoters will retain a 35 per cent stake in the company.
  
• Do the top three managers have more than 15 years of combined leadership at Sai Life Sciences?
  Yes. The company's Managing Director Krishnam Raju, and Chairman Kanumuri Ranga have been with the company since 2004 and 1999, respectively.
  
• Is the management trustworthy? Is it transparent in its disclosures, which are consistent with SEBI guidelines?
  Yes. There is no information to suggest otherwise.
  
• Is the company's accounting policy stable?
  Yes. There is no information to suggest otherwise.
  
• Is Sai Life Sciences free of promoter pledging of its shares?
  No. The promoters have pledged 2.46 per cent of their shareholding (pre-IPO).

Financials

• Did the company generate a current and three-year average return on equity of more than 15 per cent and a return on capital employed of more than 18 per cent?
  No. It has a three-year average ROE and ROCE of around 4 and 5 per cent, respectively. In FY24, it reported an ROE and ROCE of nearly 9 per cent each.
  
• Was the company's operating cash flow positive during the last three years?
  Yes. It reported a positive cash flow from operations in the last three years.
  
• Is the company's net debt-to-equity ratio less than one?
  Yes. As of Q2 FY25, the company's net debt-to-equity ratio was 0.8 times.
  
• Is the company free from reliance on huge working capital for day-to-day affairs?
  No. The company has significant working capital requirements.
  
• Can the company run its business without relying on external funding in the next three years?
  Yes. The company is profitable and free cash flow positive, so it may not have to rely on external funding.
  
• Is the company free from meaningful contingent liabilities?
  Yes. The company's contingent liabilities stood at 2.5 per cent of its net worth as of Q2 FY25.

Valuations

• Does the stock offer an operating earnings yield of more than 8 per cent on its enterprise value?
  No. The stock offers an operating earnings yield of 2 per cent on its enterprise value.
  
• Is the stock's price-to-earnings less than its peers' median level?
  No. The stock is valued at a P/E ratio of 92 times compared to its peers' median level of 86 times.
  
• Is the stock's price-to-book value less than its peers' average level?
  Yes. The stock is valued at a P/B ratio of nearly 6 times compared to its peers' average level of 12 times.

Assessing an IPO requires a careful evaluation of a company's strengths, weaknesses, and growth potential, just like we've outlined for Sai Life Sciences. But wealth creation can only be achieved through a well-researched, balanced stock portfolio. Our Value Research Stock Advisor can help you with that. What do you get? Meticulously researched stock recommendations and ready-to-invest portfolios, updated every month. Subscribe to Value Research Stock Advisor today and take charge of your financial future.

Disclaimer: This is not a stock recommendation. Investors should do their due diligence before investing.

Also read: Mobikwik IPO analysis